Log in with your email address username.


[Comment] Tocilizumab for systemic sclerosis: implications for future trials

Systemic sclerosis is a chronic autoimmune disease that causes high morbidity and increases mortality. Although treatments have become available for some manifestations such as pulmonary arterial hypertension, there is still no approved therapy for fibrotic manifestations and the overall course of disease.1 However, following findings about the pathogenesis of fibrotic diseases, several new targeted therapies are being tested in clinical studies.2,3